Japanese journal of clinical oncology最新文献

{"title":"Awareness and implementation of comprehensive genomic profiling and cancer support for adolescents and young adults among healthcare professionals in Osaka, Japan.","authors":"Tsutomu Nishida, Miwa Miyamoto, Junko Yasuda, Yukie Ninomiya, Satoru Kosugi, Masao Mizuki, Hidetoshi Eguchi, Hiroshi Imamura","doi":"10.1093/jjco/hyae159","DOIUrl":"10.1093/jjco/hyae159","url":null,"abstract":"<p><strong>Background: </strong>Comprehensive genomic profiling (CGP) and specialized support for adolescent and young adult (AYA) cancer patients are crucial yet underexplored areas of healthcare in Japan. This study investigated awareness of CGP testing and support for AYA cancer patients among healthcare professionals in Osaka.</p><p><strong>Methods: </strong>An anonymous online survey was conducted from 31 January to 31 March 2024. The survey targeted all staff, including doctors, nurses, technicians, pharmacists and others, from eight Toyono Medical Area Cancer Medical Network Council hospitals. The survey included questions on basic demographics, awareness of CGP testing and support provided to patients with AYA cancer.</p><p><strong>Results: </strong>Among the 720 respondents, 41.9% were aware of CGP testing, while 20.3% were unaware. Regarding AYA cancer, 60.7% were aware and 14.3% were unaware. Only 7.5% had frequent contact with AYA patients and 96.8% recognized the need for education and information. Awareness of CGP was greater among doctors (72.5%) than among other professionals (34.4%); similarly, AYA cancer awareness was higher among doctors (73.9%) than among other professionals (57.7%). CGP awareness among doctors varied by years of experience and institutional type, being highest in core and cooperative hospitals (80 and 78.6%, respectively) and among doctors with more than 21 years of experience (90%).</p><p><strong>Conclusions: </strong>This study reveals significant gaps in CGP and AYA cancer awareness among healthcare professionals in Osaka, Japan, with doctors demonstrating higher awareness levels than other professionals. There is a pressing need for targeted educational programs to enhance the understanding and implementation of CGP and support AYA cancer patients.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"246-252"},"PeriodicalIF":1.9,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142583057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcome of osimertinib-treated patients with epidermal growth factor receptor mutation-positive nonsmall cell lung cancer requiring dose reduction: a secondary analysis of the Reiwa study.","authors":"Nobuyasu Awano, Kiyotaka Yoh, Kazuhiro Usui, Yukio Hosomi, Kazuma Kishi, Go Naka, Kageaki Watanabe, Shu Tamano, Kohei Uemura, Hideo Kunitoh","doi":"10.1093/jjco/hyae173","DOIUrl":"10.1093/jjco/hyae173","url":null,"abstract":"<p><strong>Background: </strong>Osimertinib is effective in patients with epidermal growth factor receptor (EGFR) mutation-positive nonsmall cell lung cancer (NSCLC). However, some patients require osimertinib dose reduction because of adverse events. This study assessed the characteristics of osimertinib dose reduction and compared the efficacies of reduced-dose and regular-dose osimertinib.</p><p><strong>Methods: </strong>This multicenter, prospective, observational study enrolled patients with EGFR mutation-positive NSCLC who started first-line osimertinib treatment between September 2018 and August 2020. We categorized the patients into two groups: those who required dose reduction during osimertinib treatment (reduction group) and those who continued osimertinib treatment at a dose of 80 mg/day without dose reduction (nonreduction group). The primary endpoints were progression-free survival (PFS) and pattern of progression, whereas the secondary endpoints included overall survival (OS) and reasons for osimertinib dose reduction.</p><p><strong>Results: </strong>Of the included 575 patients, 175 (30.4%) and 400 (69.6%) were classified into the reduction and nonreduction groups, respectively. PFS was significantly better in the reduction group than in the nonreduction group [hazard ratio (HR) = 0.67, 95% confidence interval (CI) = 0.54-0.84; P <0.001]. Meanwhile, the pattern of progression and OS (HR = 0.82, 95% CI = 0.62-1.08; P = 0.15 ) did not differ significantly between the two groups. Osimertinib was reduced due to physician's decision or adverse events and the main reasons were rash and gastrointestinal symptoms such as nausea and diarrhea.</p><p><strong>Conclusions: </strong>Many patients require osimertinib dose reduction due to adverse events, but this process does not adversely affect the drug efficacy.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"261-268"},"PeriodicalIF":1.9,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142824167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-world data of first-line treatment with pembrolizumab for NSCLC with high PD-L1 expression in elderly patients: a subgroup analysis of HOT/NJLCG2001.","authors":"Kazunari Tateishi, Hidenori Mizugaki, Yasuyuki Ikezawa, Ryo Morita, Keiki Yokoo, Toshiyuki Sumi, Mari Aso, Hajime Kikuchi, Atsushi Nakamura, Motoki Sekikawa, Fumiaki Yoshiike, Yasuo Kitamura, Nozomu Kimura, Tsutomu Hachiya, Kyoji Tsurumi, Toshihiko Agatsuma, Furuta Megumi, Keiichi Nakamura, Daisuke Jingu, Hiroshi Yamamoto, Makoto Kosaka, Hiroshi Yokouchi","doi":"10.1093/jjco/hyae168","DOIUrl":"10.1093/jjco/hyae168","url":null,"abstract":"<p><strong>Background: </strong>In the first-line treatment of elderly patients with advanced-stage non-small cell lung cancer (NSCLC) with high programmed death-ligand 1 (PD-L1) expression (tumor proportion score ≥ 50%), this study aimed to determine whether pembrolizumab monotherapy (MONO) or pembrolizumab plus platinum-based chemotherapy (COMB) should be selected.</p><p><strong>Methods: </strong>We performed a retrospective multicenter study (sub-analysis of the HOT/NJLCG2001 trial) of 299 patients with NSCLC with high PD-L1 expression who received MONO or COMB as the first-line treatment between December 2018 and January 2020. We selected patients aged 75 years and older and assessed the clinical efficacy and toxicity.</p><p><strong>Results: </strong>In total, 81 (median age: 79 years) and 19 (median age: 76 years) patients received MONO and COMB, respectively. Twenty patients with a performance status (PS) score of 2-3 were enrolled in the MONO group. The median progression-free survival (PFS) was 7.8 and 8.9 months in the MONO and COMB groups, respectively. The median overall survival (OS) was 14.6 and 20.3 months, and the 2-year survival rates were 38.8 and 49.9%, respectively. Furthermore, 29.6% and 26.3% of patients discontinued treatment due to adverse events, respectively. In MONO, patients with PS 0-1 had a longer PFS (10.5 months) and OS (21.7 months) than those with PS 2-3 (0.7 and 1.6 months, respectively).</p><p><strong>Conclusion: </strong>Some elderly patients with NSCLC and high PD-L1 expression might benefit from COMB; however, MONO is considered the preferred treatment. MONO may not be an effective or feasible treatment for patients with PS 2-3, even with high PD-L1 expression.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"253-260"},"PeriodicalIF":1.9,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882503/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142828733","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Observational study of the efficacy and safety of first-line osimertinib and later treatments for uncommon epidermal growth factor receptor-activating mutation-positive advanced non-small cell lung cancer.","authors":"Tsuyoshi Hirata, Kageaki Watanabe, Yukio Hosomi, Kiyotaka Yoh, Kazuhiro Usui, Kazuma Kishi, Go Naka, Shu Tamano, Kohei Uemura, Hideo Kunitoh","doi":"10.1093/jjco/hyae176","DOIUrl":"10.1093/jjco/hyae176","url":null,"abstract":"<p><strong>Introduction: </strong>Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is a first-line therapy for advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations, including both sensitizing and T790M resistance mutations. Its real-world efficacy against uncommon EGFR mutations remains under-researched.</p><p><strong>Methods: </strong>The REIWA study, a multicentric, prospective, observational study conducted in Japan from September 2018 to August 2020, enrolled patients with advanced or recurrent EGFR mutation-positive NSCLC receiving osimertinib. Data on clinical outcomes, safety, disease progression, and subsequent treatments were collected for patients with uncommon EGFR mutations.</p><p><strong>Results: </strong>Of 583 patients receiving osimertinib, 39 (6.7%) had an uncommon EGFR mutation. The present study included 32 of these patients after excluding seven patients with an exon 20 insertion mutation. The overall objective response rate was 53.1% [95% confidence interval (CI): 36.4-69.1], and the disease control rate was 78.1% (95% CI: 61.0-89.3). The median progression-free survival was 9.4 months (95% CI: 5.0-20.0), and the median overall survival (OS) was 21.8 (95% CI: 14.4-NA) months. Notably, patients with an exon21 L861Q mutation had a significantly longer OS than those with an exon18 G719X mutation, the respective values being 37.8 and 9.7 months (hazard ratio: 0.29; 95% CI: 0.10-0.85; P = 0.02). The rate of grade 3 or worse adverse events was 10.3%. Seven out of 32 (21.9%) patients showed progression involving only the central nervous system.</p><p><strong>Conclusions: </strong>Osimertinib demonstrated efficacy and tolerability in the clinical setting in patients with uncommon EGFR mutation-positive NSCLC.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"269-274"},"PeriodicalIF":1.9,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11882500/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142864104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A classification using CRP and AFP in predicting survival of early- and intermediate-stage HCC treated with TACE.","authors":"Manabu Hayashi, Yosuke Takahata, Naoto Abe, Tatsuro Sugaya, Masashi Fujita, Kazumichi Abe, Atsushi Takahashi, Hiromasa Ohira","doi":"10.1093/jjco/hyaf041","DOIUrl":"https://doi.org/10.1093/jjco/hyaf041","url":null,"abstract":"<p><strong>Background: </strong>The aim of the present study was to investigate the association of C-reactive protein (CRP) and alpha-fetoprotein (AFP) (CRP-AFP) classification with prognosis in early- and intermediate-stage hepatocellular carcinoma (HCC) patients after undergoing transcatheter arterial chemoembolization (TACE).</p><p><strong>Methods: </strong>This retrospective observational study included 313 early- and intermediate-stage HCC patients who had undergone TACE. We calculated CRP-AFP score by assigning two points for CRP ≥ 1.0 mg/ml and AFP ≥ 100 ng/ml, and 1 point for CRP levels of 0.2-1.0 mg/ml. The patients were categorized into three classes according to CRP-AFP score; class A (0 points), class B (1 point), and class C (2-4 points).</p><p><strong>Results: </strong>The median CRP levels were 0.14 mg/dl and the median AFP levels were 31 ng/ml. The numbers of patients in CRP-AFP classes A, B, and C were 112, 69, and 132, respectively. The median survival times of classes A, B, and C were 42.2 months, 21.5 months, and 13.2 months, respectively. CRP-AFP class was associated with prognosis independent of mALBI grade and tumor burden calculated by up-to-7 criteria (hazard ratio, 1.57; 95% confidence interval, 1.30-1.89; P < .001). The time-dependent area under the receiver operating characteristic curve of CRP-AFP class was consistently higher than those of the STATE score and modified hepatoma arterial embolization prognostic score.</p><p><strong>Conclusions: </strong>Our findings suggest that CRP-AFP classification serves as a simple and effective prognostic tool for post-TACE early- and intermediate-stage HCC patients.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative surgical invasiveness of internal fixation for pathological fractures in metastatic bone disease versus traumatic fractures: a quantitative analysis of operative time and blood loss.","authors":"Katsuhiro Hayashi, Satoshi Takenaka, Shusa Ohshika, Hiroyuki Kawashima, Makoto Endo, Eisuke Kobayashi, Eiji Nakata, Tomoki Nakamura, Keisuke Horiuchi, Tetsuya Hamada, Yoshihiro Nishida, Takeshi Morii","doi":"10.1093/jjco/hyaf039","DOIUrl":"https://doi.org/10.1093/jjco/hyaf039","url":null,"abstract":"<p><strong>Objective: </strong>The primary aim of this study was to compare the surgical invasiveness of internal fixation for pathological fractures caused by metastatic bone tumors with that for traumatic fractures. The secondary aim was to identify factors contributing to the complexity of surgeries for metastatic bone disease and provide insights for improving surgical strategies by analyzing operative time and blood loss.</p><p><strong>Methods: </strong>Patients undergoing internal fixation for femoral fractures at 10 institutions between January 2021 and December 2023 were included. Traumatic and metastatic pathological fractures were analyzed, excluding patients aged <18 years and those with benign or atypical fractures. Factors influencing blood loss and operative time were assessed using univariate regression and multivariate modeling (P < 0.05).</p><p><strong>Results: </strong>A total of 275 patients (male = 97, female = 178) with a mean age of 76 years were included. Patients had 230 traumatic and 45 metastatic fractures, with proximal fractures being the most common (n = 225). Intramedullary nailing was the predominant fixation method (n = 231). Blood loss and operative times were significantly affected by the fracture cause, site, and reduction procedures (P < 0.05). Metastatic, distal, or diaphyseal fractures and reduction procedures resulted in higher blood loss and longer operative times. Multivariate analysis confirmed these factors as significant predictors.</p><p><strong>Conclusions: </strong>Surgeries for metastatic fractures are more invasive than those for traumatic fractures because of compromised bone integrity and procedural complexity. Operative time is a key indicator of surgical invasiveness, highlighting the need for tailored surgical approaches to manage metastatic bone disease effectively.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term clinical outcomes after salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy.","authors":"Kenta Onishi, Yasushi Nakai, Fumisato Maesaka, Mitsuru Tomizawa, Takuto Shimizu, Shunta Hori, Daisuke Gotoh, Makito Miyake, Kazumasa Torimoto, Kaori Yamaki, Isao Asakawa, Fumiaki Isohashi, Kiyohide Fujimoto, Nobumichi Tanaka","doi":"10.1093/jjco/hyaf037","DOIUrl":"https://doi.org/10.1093/jjco/hyaf037","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to evaluate the clinical outcomes of patients who developed prostate-specific antigen failure after radical prostatectomy and were treated with salvage radiotherapy (SRT).</p><p><strong>Methods: </strong>This retrospective study included 167 patients who received SRT between January 2008 and August 2017 at a single center. Cumulative and periodic genitourinary and gastrointestinal adverse events and the chronologic changes in quality of life were evaluated before and 1, 3, 6, 12, 24, 36, 48, and 60 months after SRT.</p><p><strong>Results: </strong>The median follow-up duration after SRT was 83 months. The 5- and 7-year biochemical recurrence-free rates were 52.6% and 47.9%, respectively. Multivariate analysis revealed the following independent risk factors for recurrence after SRT: higher total Gleason score (≥8), higher pathological T stage, negative resection margin, and shorter period between radical prostatectomy and biochemical recurrence-free. The cumulative incidence rates of grade 2 or higher genitourinary and gastrointestinal adverse events after SRT were 27.4% and 9.4%, respectively. Bowel function worsened after SRT and showed significant deterioration 5 years after SRT, compared with pre-treatment. Five years post SRT, the rates of patients whose physical and mental component scores were < 50 were 44.1% and 34.3%, respectively.</p><p><strong>Conclusions: </strong>Prostate-specific antigen recurrence occurred in approximately half of the patients after SRT, with a higher Gleason score, higher pathological T stage, negative resection margin, and shorter period between radical prostatectomy and first biochemical recurrence identified as risk factors. Besides the adverse events, careful attention to long-term quality-of-life deterioration must be considered when considering indications for SRT.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-02-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143556850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Valuable predictive power of prognostic nutritional index in metastatic breast cancer patients treated with CDK4/6 inhibitors.","authors":"Tuğba Önder, İrem Öner, Cengiz Karaçin, Öztürk Ateş","doi":"10.1093/jjco/hyaf036","DOIUrl":"https://doi.org/10.1093/jjco/hyaf036","url":null,"abstract":"<p><strong>Aims and objectives: </strong>The prognostic value of nutritional status in HR+/HER2- metastatic breast cancer (mBC) patients treated with CDK4/6 inhibitors (CDK4/6is) and endocrine therapy (ET) is unclear.</p><p><strong>Methods/materials: </strong>The effect of PNI values before starting CDK 4/6i on patient prognosis was retrospectively analyzed.</p><p><strong>Results: </strong>A total of 431 patients were evaluated. After 35.7 months of follow-up, the median overall survival (mOS) was 46.3 months (95% CI, 29.7-62.8). The PNI-low group had decreased progression-free survival compared to the PNI-high group [16.6 vs. 30.5 months; univariate HR = 1.640, 95% confidence interval (CI): 1.281-2.099, P < .001]. The PNI-low group's mOS was noticeably shorter than the PNI-high group (35.0 months vs. not reached; multivariate-adjusted HR: 2.082, 95% CI: 1.398-3.102, P < .001). When stratified by CDK4/6i line: In patients using CDK4/6i as the first line, mPFS for the PNI-low and PNI-high group was 24.6 vs. 35.6 months (P = .026), and survival probabilities at 24, 36, and 48 months in the PNI-low and PNI-high groups were 75%, 62%, 57%, and 88%, 80%, and 72%, respectively (P = .002). In patients using CDK4/6i as the second line and after, mPFS was 8.2 vs.12.0 months (P = .014), and mOS was 18.6 vs. 39.6 months (P = .001) for the PNI-low and PNI-high group, respectively. The ORR and DCR were significantly lower in the low-PNI group than in the high-PNI group (P = .018 and P = .017, respectively). The incidence of grade 3-4 side effects due to CDK4/6is (39.8% vs. 30.7%, P = .046) was significantly greater in the PNI-low group than in the PNI-high group.</p><p><strong>Conclusions: </strong>This study's results suggest that PNI is an easily measured and reliable indicator of prognosis in mBC patients treated with CDK4/6i and ET.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obinutuzumab maintenance versus observation for patients with newly diagnosed high tumor burden follicular lymphoma who achieved complete metabolic response after obinutuzumab plus bendamustine induction therapy: a multicenter, randomized, phase III study (JCOG2008, MAIN study).","authors":"Tsutomu Kobayashi, Kenichi Ishizawa, Ryunosuke Machida, Ryo Sadachi, Keita Sasaki, Haryoon Kim, Keisuke Kataoka, Wataru Munakata, Noriko Fukuhara, Hirokazu Nagai","doi":"10.1093/jjco/hyaf038","DOIUrl":"https://doi.org/10.1093/jjco/hyaf038","url":null,"abstract":"<p><p>Maintenance therapy with monoclonal anti-CD20 antibody is the standard approach in patients with follicular lymphoma who initially treated and achieved response to immunochemotherapy. Maintenance therapy reduces the risk of lymphoma progression, but the risk of late or delayed fatal treatment-emergent adverse events is a clinically important issue. The aim of this randomized phase III study is to confirm the non-inferiority of observation compared to obinutuzumab maintenance therapy in patients with untreated high tumor burden follicular lymphoma who achieved complete metabolic response after obinutuzumab plus bendamustine induction therapy (JCOG2008, MAIN study). The first registration is performed before obinutuzumab plus bendamustine administration. Those who achieved complete metabolic response at the end of induction are included in the second registration and randomized to an obinutuzumab maintenance arm or observation only. This study has been registered in the Japan Registry for Clinical Trials as jRCT1031210379.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143491878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of the number of prior androgen receptor pathway inhibitors before cabazitaxel treatment in patients with metastatic castration-resistant prostate cancer.","authors":"Hisanori Taniguchi, Junichi Ikeda, Yuki Masuo, Hidefumi Kinoshita","doi":"10.1093/jjco/hyaf034","DOIUrl":"https://doi.org/10.1093/jjco/hyaf034","url":null,"abstract":"<p><strong>Objective: </strong>Cabazitaxel (CAZ) has been shown to prolong overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) following docetaxel treatment. However, the impact of the number of prior androgen receptor pathway inhibitors (ARPIs) on CAZ efficacy remains unclear. This study aimed to analyze the effectiveness of CAZ based on the number of prior ARPIs administered before CAZ treatment.</p><p><strong>Methods: </strong>A retrospective review was conducted on mCRPC patients who received CAZ. The differences in CAZ efficacy based on the number of prior ARPIs were evaluated and prognostic factors for prostate-specific antigen (PSA) progression-free survival (PFS) and OS were analyzed.</p><p><strong>Results: </strong>A total of 59 patients were categorized into three groups: 12 patients with no prior ARPI, 26 with one prior ARPI, and 21 with two or more prior ARPIs. The median number of CAZ cycles and relative dose intensity were 5% and 60%, respectively. No significant differences were observed in PSA response or PFS among the three groups. Although OS from the first CAZ administration did not significantly differ among the groups, the OS from mCRPC diagnosis was shorter in the group with no prior ARPI. Multivariate analysis identified a time to mCRPC diagnosis of less than 11 months and low serum hemoglobin levels before CAZ administration as significant prognostic factors of poor OS following CAZ treatment.</p><p><strong>Conclusions: </strong>PSA response, PFS, and OS after CAZ administration did not significantly differ based on the number of prior ARPIs. CAZ efficacy appears consistent regardless of the number of prior ARPI sequences.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":""},"PeriodicalIF":1.9,"publicationDate":"2025-02-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143482922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}